TY - JOUR
T1 - Outcomes That Matter to Adolescents With Continuous Headache Due to Chronic Migraine and Their Parents
AU - Morris, Cynthia
AU - Ross, Alexandra
AU - Greene, Kaitlin
AU - Irwin, Samantha
AU - Wagstaff, Amanda
AU - Gelfand, Amy
N1 - Funding Information:
C. Morris and A.C. Ross report no disclosures. K. Greene has received research support through the International Headache Academy through the American Headache Society. She is the site principal investigator for a USB-sponsored clinical trial of Qudexy XR in pediatric patients for which her institution receives financial support. S. Irwin receives honoraria for writing a chapter for the Canadian Pharmacy Association and from NeuroDiem, compensation for scientific consulting (Impel NeuroPharma Inc, Biohaven Pharmaceuticals, and Lundbeck A/S), and research support from the Duke Clinical Research Institute. A. Wagstaff reports no disclosures In the last 12 months, A. Gelfand has received honoraria from UpToDate (for authorship) and JAMA Neurology. She receives payment from the American Headache Society for her role as editor of Headache. She received grant support from the Duke Clinical Research Institute and the UCSF Resource Allocation Program. Her spouse reports research support (to UCSF) from Genentech for a clinical trial, honoraria for editorial work for Dynamed plus, and personal compensation for medical-legal consulting. Go to Neurology.org/N for full disclosures.
Funding Information:
This study was funded by a grant from Amgen (principal investigator: Dr. Gelfand).
Publisher Copyright:
© American Academy of Neurology.
PY - 2022/6/7
Y1 - 2022/6/7
N2 - Background and ObjectivesChildren and adolescents with chronic migraine who have continuous headache may have high levels of headache-related disability but have largely been excluded from clinical trials. Understanding patient-valued treatment outcomes may facilitate future study design. The aim of this work was to identify patient-valued outcome measures for headache preventive treatments among adolescents with continuous headache due to chronic migraine and their parents.MethodsAdolescents with an International Classification of Headache Disorders, 3rd edition diagnosis of chronic migraine, who had continuous headache and who were being cared for at a tertiary pediatric headache clinic, and their parents were surveyed to query the value of treatment outcomes in the domains of headache frequency, intensity, functional impact, and associated symptoms. Individual outcomes and categories of outcomes were ranked in order of preference using weighted average rank. Results were rounded to the degree of precision with which they were measured.ResultsThe survey was completed by 55 adolescents and 60 parents of adolescents with continuous headache due to chronic migraine. Mean age of adolescents was 16 (SD 1, range 12-17) years. Median adolescent-reported duration of continuous headache was 24 (interquartile range [IQR] 12-39) months, and adolescents had tried a median of 2 (IQR 0-5) preventive medications, only 13% of which were perceived as helpful. Overall, the most valued individual outcome measure among both adolescents and parents was a decrease in frequency of more severe headaches; however, outcomes reflecting headache intensity were most valued by adolescents, while outcomes reflecting functional impact were most valued by parents. More than 60% of adolescents felt that it was more important to measure decrease in frequency and intensity of headaches in terms of severe headaches/spikes rather than total headache days. Among associated symptoms, improvement in brain fog was most highly valued by both adolescents and parents.DiscussionThe results of this study provide important information about which preventive treatment outcomes are valued by adolescents with continuous headache due to chronic migraine and their parents. Results suggest that adolescents value a decrease in frequency of severe headaches over a decrease in frequency of headache days overall. Generalizability may be limited because the surveyed population was being cared for at a tertiary pediatric headache clinic and generally had headache disorders that were refractory to treatment. These results may help guide future trial design in this population with continuous headache due to chronic migraine.
AB - Background and ObjectivesChildren and adolescents with chronic migraine who have continuous headache may have high levels of headache-related disability but have largely been excluded from clinical trials. Understanding patient-valued treatment outcomes may facilitate future study design. The aim of this work was to identify patient-valued outcome measures for headache preventive treatments among adolescents with continuous headache due to chronic migraine and their parents.MethodsAdolescents with an International Classification of Headache Disorders, 3rd edition diagnosis of chronic migraine, who had continuous headache and who were being cared for at a tertiary pediatric headache clinic, and their parents were surveyed to query the value of treatment outcomes in the domains of headache frequency, intensity, functional impact, and associated symptoms. Individual outcomes and categories of outcomes were ranked in order of preference using weighted average rank. Results were rounded to the degree of precision with which they were measured.ResultsThe survey was completed by 55 adolescents and 60 parents of adolescents with continuous headache due to chronic migraine. Mean age of adolescents was 16 (SD 1, range 12-17) years. Median adolescent-reported duration of continuous headache was 24 (interquartile range [IQR] 12-39) months, and adolescents had tried a median of 2 (IQR 0-5) preventive medications, only 13% of which were perceived as helpful. Overall, the most valued individual outcome measure among both adolescents and parents was a decrease in frequency of more severe headaches; however, outcomes reflecting headache intensity were most valued by adolescents, while outcomes reflecting functional impact were most valued by parents. More than 60% of adolescents felt that it was more important to measure decrease in frequency and intensity of headaches in terms of severe headaches/spikes rather than total headache days. Among associated symptoms, improvement in brain fog was most highly valued by both adolescents and parents.DiscussionThe results of this study provide important information about which preventive treatment outcomes are valued by adolescents with continuous headache due to chronic migraine and their parents. Results suggest that adolescents value a decrease in frequency of severe headaches over a decrease in frequency of headache days overall. Generalizability may be limited because the surveyed population was being cared for at a tertiary pediatric headache clinic and generally had headache disorders that were refractory to treatment. These results may help guide future trial design in this population with continuous headache due to chronic migraine.
UR - http://www.scopus.com/inward/record.url?scp=85131514034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131514034&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000200292
DO - 10.1212/WNL.0000000000200292
M3 - Article
C2 - 35418460
AN - SCOPUS:85131514034
VL - 98
SP - E2347-E2355
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 23
ER -